2013
DOI: 10.7861/clinmedicine.13-6-585
|View full text |Cite
|
Sign up to set email alerts
|

Drug therapies in liver disease

Abstract: -The likelihood of a general physician encountering a patient with compensated and decompensated liver disease is increasing. This article provides an overview of pharmaceutical agents currently used in the management of cirrhosis and is designed to allow a better understanding of the rationale for using certain drugs in patients with often complex pathology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 65 publications
0
1
0
Order By: Relevance
“…Physiologically, these pericytes secrete α-SMA that is responsible for connective tissue formation in response to liver injury, and α-SMA is commonly used as a marker of myofibroblast formation [3,4]. Liver lesions from fibrosis are difficult to cure, but clinical interventions may block further development or reduce related complications [5]. However, current medications for managing hepatofibrosis are limited due to unwanted side effects [6].…”
Section: Introductionmentioning
confidence: 99%
“…Physiologically, these pericytes secrete α-SMA that is responsible for connective tissue formation in response to liver injury, and α-SMA is commonly used as a marker of myofibroblast formation [3,4]. Liver lesions from fibrosis are difficult to cure, but clinical interventions may block further development or reduce related complications [5]. However, current medications for managing hepatofibrosis are limited due to unwanted side effects [6].…”
Section: Introductionmentioning
confidence: 99%